View in EDS

Cell-resolved high-dimensional imaging analysis, therapeutic modeling, and a Phase Ib clinical study establish BCL-2 as a target across heterogeneous CRPC subtypes.

Saved in:
Bibliographic Details
Title: Cell-resolved high-dimensional imaging analysis, therapeutic modeling, and a Phase Ib clinical study establish BCL-2 as a target across heterogeneous CRPC subtypes.
Authors: Jamroze A; Department of Pharmacology & Therapeutics, Roswell Park Comprehensive Cancer Center, Buffalo, NY 14263, USA., Liu X; Department of Pharmacology & Therapeutics, Roswell Park Comprehensive Cancer Center, Buffalo, NY 14263, USA., Hou S; Department of Biostatistics & Bioinformatics, Roswell Park Comprehensive Cancer Center, Buffalo, NY 14263, USA., Li WJ; Department of Pharmacology & Therapeutics, Roswell Park Comprehensive Cancer Center, Buffalo, NY 14263, USA.; Experimental Therapeutics (ET) Graduate Program, Roswell Park Comprehensive Cancer Center and the University at Buffalo, Buffalo, NY 14263, USA., Yu H; Department of Biostatistics & Bioinformatics, Roswell Park Comprehensive Cancer Center, Buffalo, NY 14263, USA., Tracz A; Department of Pharmacology & Therapeutics, Roswell Park Comprehensive Cancer Center, Buffalo, NY 14263, USA., Li Q; Department of Pharmacology & Therapeutics, Roswell Park Comprehensive Cancer Center, Buffalo, NY 14263, USA., Nastiuk K; Departments of Cancer Genetics and Urology, Roswell Park Comprehensive Cancer Center, Buffalo, NY 14263, USA., Chen X; Department of Pharmacology & Therapeutics, Roswell Park Comprehensive Cancer Center, Buffalo, NY 14263, USA., Huang J; Department of Pathology, Duke University School of Medicine, Durham, NC 27710 USA., Lin K; Department of Epigenetics and Molecular Carcinogenesis, the University of Texas M.D Anderson Cancer Center, 1515 Holcombe Blvd., Houston, TX 77030, USA., Lu Y; Department of Epigenetics and Molecular Carcinogenesis, the University of Texas M.D Anderson Cancer Center, 1515 Holcombe Blvd., Houston, TX 77030, USA., Puzanov I; Department of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, NY 14263, USA., Kirk JS; Department of Pharmacology & Therapeutics, Roswell Park Comprehensive Cancer Center, Buffalo, NY 14263, USA., Chatta G; Department of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, NY 14263, USA., Tang DG; Department of Pharmacology & Therapeutics, Roswell Park Comprehensive Cancer Center, Buffalo, NY 14263, USA.; Experimental Therapeutics (ET) Graduate Program, Roswell Park Comprehensive Cancer Center and the University at Buffalo, Buffalo, NY 14263, USA.
Source: BioRxiv : the preprint server for biology [bioRxiv] 2025 Jul 23. Date of Electronic Publication: 2025 Jul 23.
Publication Type: Journal Article; Preprint
Journal Info: Country of Publication: United States NLM ID: 101680187 Publication Model: Electronic Cited Medium: Internet ISSN: 2692-8205 (Electronic) Linking ISSN: 26928205 NLM ISO Abbreviation: bioRxiv Subsets: PubMed not MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:2692-8205
DOI:10.1101/2025.07.08.663739